One thing that often comes up is why don’t all inflamed tumours respond to immune checkpoint blockade or immunotherapy – it is that PD-L1 is a weak biomarker of response or are there factors that can explain the phenomenon?
Some new research now sheds some light on the issue.
This seemed to be a great opportunity to explore several topics around this theme and look at what the data from AACR and ASCO are potentially telling us.
Obviously we need to see the presentations in Chicago to be sure, but the good thing is that there are some good hints of where to start and what to think about going forward since they could have an impact on clinical trial design.
With a lot of observers focused on some disappointing results from, for example, Incyte’s epacadostat (IDO) and Jounce’s ICOS antibody, are there things we can do to improve the chances of success?